Treatment With HRS-3/A9 — Response and Side Effects
| Patient No. . | Dose HRS-3/A9 . | Response . | Response Duration (mo) . | HRS-3/A9–Related Side Effects* . |
|---|---|---|---|---|
| 1 | 1 mg/m2 ×4 | Progressive | None | |
| 2 | 1 mg/m2 ×4 | MR | 2 | None |
| 3 | 2 mg/m2 ×2 | Progressive | Pain in involved LNs (II°) | |
| 4 | 2 mg/m2 ×2 | Progressive | Pain in involved LNs (I°), fever (II°) | |
| 5 | 2 mg/m2 ×4 | MR | 1 | None |
| 6 | 4 mg/m2 ×4 | PR | 3 | None |
| 7 | 4 mg/m2 ×4 | Mixed response | Allergic exanthema (II°) | |
| 8 | 8 mg/m2 ×4 | MR | 11+ | None |
| 9 | 8 mg/m2 ×4 | Stable disease | 10+ | None |
| 10 | 16 mg/m2 ×4 | Progressive | Fever (I°) | |
| 11 | 16 mg/m2 ×4 | Progressive | Fever (I°) | |
| 12 | 32 mg/m2 ×4 | Stable disease | 2 | None |
| 13 | 32 mg/m2 ×4 | Progressive | Fever (II°), hypotension (I°) | |
| 14 | 64 mg/m2 ×4 | Progressive | None | |
| 15 | 64 mg/m2 ×4 | CR | 6 | None |
| Patient No. . | Dose HRS-3/A9 . | Response . | Response Duration (mo) . | HRS-3/A9–Related Side Effects* . |
|---|---|---|---|---|
| 1 | 1 mg/m2 ×4 | Progressive | None | |
| 2 | 1 mg/m2 ×4 | MR | 2 | None |
| 3 | 2 mg/m2 ×2 | Progressive | Pain in involved LNs (II°) | |
| 4 | 2 mg/m2 ×2 | Progressive | Pain in involved LNs (I°), fever (II°) | |
| 5 | 2 mg/m2 ×4 | MR | 1 | None |
| 6 | 4 mg/m2 ×4 | PR | 3 | None |
| 7 | 4 mg/m2 ×4 | Mixed response | Allergic exanthema (II°) | |
| 8 | 8 mg/m2 ×4 | MR | 11+ | None |
| 9 | 8 mg/m2 ×4 | Stable disease | 10+ | None |
| 10 | 16 mg/m2 ×4 | Progressive | Fever (I°) | |
| 11 | 16 mg/m2 ×4 | Progressive | Fever (I°) | |
| 12 | 32 mg/m2 ×4 | Stable disease | 2 | None |
| 13 | 32 mg/m2 ×4 | Progressive | Fever (II°), hypotension (I°) | |
| 14 | 64 mg/m2 ×4 | Progressive | None | |
| 15 | 64 mg/m2 ×4 | CR | 6 | None |
Abbreviation: LN, lymph node.
All side effects (except for the allergic exanthema) disappeared within less than 8 hours.